<DOC>
	<DOCNO>NCT01005407</DOCNO>
	<brief_summary>The purpose study evaluate safety , immunogenicity lot-to-lot consistency investigational hepatitis B virus vaccine , HEPLISAV™ , healthy adult 40 70 year age</brief_summary>
	<brief_title>Safety , Immunogenicity , Lot-to-lot Consistency Study Hepatitis B Virus ( HBV ) Vaccine , HEPLISAV Compared Engerix-B Vaccine</brief_title>
	<detailed_description>The purpose study evaluate safety , immunogenicity lot-to-lot consistency investigational hepatitis B virus vaccine , HEPLISAV™ , healthy adult 40 70 year age</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>40 70 year age , inclusive seronegative hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B surface antigen ( antiHBsAg ) , antibody hepatitis B core antigen ( antiHBcAg ) , human immunodeficiency virus ( HIV ) good health opinion investigator , base upon medical history , physical examination , laboratory evaluation female childbearing potential , agree consistently use highly effective method birth control screen visit treatment phase , 28 day last injection female childbearing potential , pregnant , breastfeeding , plan pregnancy history consider investigator high risk recent exposure HBV HIV ; example , current intravenous drug use unprotected sex know HBV/HIV positive partner know history autoimmune disease previously receive hepatitis B vaccine ( approved investigational )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HBV vaccine</keyword>
	<keyword>Hepatitis B vaccine</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>HBV</keyword>
	<keyword>Prevention &amp; Control</keyword>
	<keyword>Healthy</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>